Bank of New York Mellon
AUTL

Bank of New York Mellon’s Autolus Therapeutics AUTL Stock Holding History

Bank of New York Mellon’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,673,994
Closed -$3.93M – 4114
2024
Q4 		$3.93M Sell
1,673,994
-156,527
-9% -$529K ﹤0.01% 2410
2024
Q3 		$6.64M Sell
1,830,521
-701,167
-28% -$2.8M ﹤0.01% 2143
2024
Q2 		$8.81M Buy
2,531,688
+1,080,897
+75% +$4.66M ﹤0.01% 2021
2024
Q1 		$9.26M Buy
+1,450,791
New +$9.05M ﹤0.01% 1998

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon's AUTL Position: Q1 2025 in Review

Bank of New York Mellon sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 1,673,994 shares — an estimated $3.93M sold.

Bank of New York Mellon first reported a position in AUTL in Q1 2024 and held it in 4 quarters. The position peaked at $9.26M in Q1 2024. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Bank of New York Mellon reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 1,673,994 Autolus Therapeutics shares in Q1 2025, an estimated $3.93M.
  • Bank of New York Mellon first reported a position in Autolus Therapeutics in Q1 2024 and held it in 4 quarters.
  • Bank of New York Mellon's Autolus Therapeutics position peaked at $9.26M in Q1 2024.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Bank of New York Mellon's 13F filing for Q1 2025, filed 29 Apr 2025.